Liraglutide biosimilar (Newbury)

利拉鲁肽生物类似药（Newbury）

Report date: 2024/07/25 10:49:48

Base Information

Drug NameLiraglutide biosimilar (Newbury)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant polypeptideBiologics > Biosimilar
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritoryDenmark
Original Approved Date2024/06/20
Country/TerritoryDenmark
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesNewbury Pharmaceuticals AB
China Registration ClassN/A

Develop Information

Active CompaniesNewbury Pharmaceuticals AB
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A